Asia review finds substantial MRSP burden in canine pyoderma

Methicillin-resistant Staphylococcus pseudintermedius may be at least as common as methicillin-susceptible strains in canine pyoderma cases reported from Asia, according to a new systematic review and meta-analysis published May 1, 2026, in Veterinary Research Communications. Across 15 eligible studies from 2015 to 2024, the authors estimated pooled prevalence of 27.9% for MSSP and 30.7% for MRSP, with no statistically significant difference between them. They also found that MRSP isolates carried broader antimicrobial resistance, reinforcing concerns that one of small-animal practice’s most familiar skin pathogens is becoming harder to treat with routine empiric choices. (pubmed.ncbi.nlm.nih.gov)

That matters because S. pseudintermedius is already central to everyday dermatology and primary care caseloads. Recent ISCAID guidelines describe canine pyoderma as one of the most common presentations in small-animal practice and a frequent driver of antimicrobial prescribing. Earlier review literature has also framed MRSP as a growing clinical problem because it combines multidrug resistance, persistence, treatment failure, and repeated antimicrobial exposure in recurrent cases. (pmc.ncbi.nlm.nih.gov)

The new meta-analysis was focused narrowly on Asian cross-sectional studies that used disk diffusion susceptibility testing in dogs with pyoderma. Fourteen studies were included in the prevalence analysis, and the overall heterogeneity was high, suggesting important differences in geography, case mix, and testing practices across the included literature. The pooled prevalence of the mecA gene among MRSP isolates was 11.9%, and resistance patterns showed a clear split: MSSP isolates had the lowest resistance to amoxicillin-clavulanic acid and oxacillin, while MRSP isolates were more commonly resistant to oxacillin, clindamycin, and doxycycline. The authors explicitly noted that their estimates should not be treated as the “true” prevalence for all of Asia, because the analysis excluded other sample types and other susceptibility methods. (pubmed.ncbi.nlm.nih.gov)

The broader literature supports the paper’s warning that this is not just a microbiology story. A 2025 WOAH review on antimicrobial resistance in companion animals said MRSP prevalence in clinical isolates varies widely by country and clone, and emphasized that the main clinical challenge is not necessarily worse virulence, but fewer effective treatment options because MRSP is often multidrug resistant. The same review noted that recent antimicrobial exposure is a strong risk factor, and that transmission can occur within households and veterinary settings, with infected dogs shedding organisms even after clinical resolution. (woah.org)

There are also signs that the regional burden described in the meta-analysis fits with newer country-level findings. A 2025 study from Japan reported that about half of animal-derived S. pseudintermedius isolates were MRSP and found high resistance among those isolates to multiple drugs used in pyoderma treatment. Another recent Hong Kong analysis of multidrug-resistant bacterial carriage in dogs with pyoderma and otitis externa adds to the picture that resistant skin pathogens remain an active issue in parts of Asia. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this paper strengthens the case for moving culture and susceptibility testing earlier in the workup, especially in recurrent, deep, nonhealing, or previously treated pyoderma cases. ISCAID’s 2025 guidance says first-choice drugs can be expected to cover most MSSP infections, but laboratory testing should confirm susceptibility for other drugs and help rule out safer alternatives. In practical terms, a 30.7% pooled MRSP estimate means clinicians in affected settings should think carefully before relying on empiric systemic therapy alone, particularly when there’s a history of prior antibiotic exposure or treatment failure. (pubmed.ncbi.nlm.nih.gov)

The study also has stewardship implications beyond the individual case. High MRSP prevalence raises the stakes for infection control in clinics, communication with pet parents about adherence and follow-up, and careful selection of topical versus systemic therapy. It also reinforces that resistance surveillance in companion animals is still geographically uneven, a gap the WOAH review highlighted as a continuing weakness in the global evidence base. (woah.org)

What to watch: The next developments to watch are whether more standardized surveillance studies narrow the wide between-study variation seen here, whether Asian country-level data begin to show clearer shifts in dominant MRSP clones and resistance patterns, and how quickly clinicians adopt guideline-driven, susceptibility-based treatment pathways for canine pyoderma. (pubmed.ncbi.nlm.nih.gov)